(19) World Intellectual Property Organization

International Bureau
(43) International Publication Date

21 November 2013 (21.11.2013)





(10) International Publication Number WO 2013/171729 A3

(51) International Patent Classification:

| C07C 311/08 (2006.01) | C07D 263/32 (2006.01) |
|------------------------------|------------------------------|
| C07D 231/12 (2006.01) | C07D 271/06 (2006.01) |
| C07D 233/61 (2006.01) | C07D 213/40 (2006.01) |
| C07C 311/16 (2006.01) | C07D 213/61 (2006.01) |
| C07D 239/26 (2006.01) | A61K 31/395 (2006.01) |
| C07C 317/44 (2006.01) | A61K 31/167 (2006.01) |
| C07D 249/08 (2006.01) | A61P 29/00 (2006.01) |

(21) International Application Number:

PCT/IB2013/058108

(22) International Filing Date:

29 August 2013 (29.08.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| 55/MUM/2013 | 8 January 2013 (08.01.2013) | IN |
|--------------|------------------------------|----|
| 61/760,301 | 4 February 2013 (04.02.2013) | US |
| 811/MUM/2013 | 19 March 2013 (19.03.2013) | IN |

- (71) Applicant: GLENMARK PHARMACEUTICALS S.A. [CH/CH]; Chemin de la Combeta 5, CH-2300 La Chaux-de-Fonds (CH).
- (72) Inventors: CHAUDHARI, Sachin Sundarlal; 15/304, FAM C.H.S., Sector # 11, Koparkhairane, Maharashtra, Navi Mumbai 400709 (IN). THOMAS, Abraham; Flat No. 5, 11th Floor, Building No. A-6, Millennium Towers, Sector 9, Sanpada, Maharashtra, Navi Mumbai 400705 (IN). KHAIRATKAR-JOSHI, Neelima; 101, Devprayag CHS, Bhakti Mandir Rd, Hari Niwas, Panchpakhadi, Maharashtra, Thane (W) 400602 (IN). BAJPAI, Malini; 47/9 Kabir Marg (Clay Square), Uttar Pradesh, Lucknow 226001 (IN).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- upon request of the applicant, before the expiration of the time limit referred to in Article 21(2)(a)
- (88) Date of publication of the international search report:

6 February 2014

(54) Title: ARYL AND HETEROARYL AMIDE COMPOUNDS AS ROR GAMMA T MODULATOR



(57) Abstract: The present disclosure is directed to compounds of Formula (I), and pharmaceutically acceptable salts thereof, as modulator of retinoid-related orphan receptor gamma t (ROR). These compounds prevent, inhibit, or suppress the action of ROR) and are therefore useful in the treatment of ROR) mediated disease, disorder, syndrome or condition such as pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, neurodegenerative diseases or cancer.





INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2013/058108

| | | | PC 1/ 11 | 32013/058108 |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|------------------------------------------|
| INV. | FICATION OF SUBJECT MATTER C07C311/08 | 63/32 C 1/167 A | 07C311/16 07D271/06 61P29/00 | CO7D239/26 CO7D213/40 |
| B. FIELDS | SEARCHED | | | |
| | coumentation searched (classification system followed by classifiCO7D A61K A61P | cation symbols) | | |
| Dooumentat | tion searched other than minimum documentation to the extent th | at such documents | are included in the fie | lds searched |
| | ata base consulted during the international search (name of data ternal, WPI Data, BEILSTEIN Data | a base and, where | oracticable, search ter | ms used) |
| C. DOCUM | ENTS CONSIDERED TO BE RELEVANT | | | |
| Category* | Oitation of document, with indication, where appropriate, of the | relevant passages | | Relevant to claim No. |
| A | WO 2012/100734 A1 (GLAXO GROUP WANG YONGHUI [CN]; YANG TING [CN] 2 August 2012 (2012-08-02) cited in the application claims; examples | LTD [GB]; CN]) | | 1-35 |
| A | WO 2012/100732 A1 (GLAXO GROUP WANG YONGHUI [CN]; YANG TING [CON] 2 August 2012 (2012-08-02) cited in the application claims; examples | | | 1-35 |
| Furth | her documents are listed in the continuation of Box C. | X See p | atent family annex. | |
| * Special c | ategories of cited documents : | | | ne international filing date or priority |
| "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "A" document of particular relevance; the claim considered to involve an inventive step when the document of particular relevance; the claim considered to involve an inventive step when the document of particular relevance; the claim considered to involve an inventive step when the document of particular relevance; the claim considered to involve an inventive step when the document of particular relevance; the claim considered to involve an inventive step when the document of particular relevance; the claim considered to involve an inventive step when the document of particular relevance; the claim considered to involve an inventive step when the document of particular relevance; the claim considered to involve and not in conflict with the application to the principle or theory underlying the inventive principle or theory underlying the inventional principle or theory | | ig the invention is; the claimed invention cannot be considered to involve an inventive en alone is; the claimed invention cannot be itve step when the document is er such documents, such combination | | |
| "" document published prior to the international filing date but later than the priority date claimed "" document member of the same patent for | | | | |
| | actual completion of the international search | | ailing of the internation | · |
| 12 November 2013 | | 22 | 22/11/2013 | |
| Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016 | | Authorized Ze | rvas, Brigi | tte |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/IB2013/058108

| Patent document cited in search report | | Publication date | | Patent family member(s) | Publication date |
|----------------------------------------|----|---------------------|------|----------------------------|---------------------|
| WO 2012100734 | A1 | 02-08-2012 | NONE | | |
| WO 2012100732 | A1 | 02-08-2012 | NONE | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |